Sustained Release Capsules

• Omez DSR+ is contraindicated in patients with known hypersensitivity to Esomeprazole or other substituted benzimidazoles or to Domperidone or other dopamine antagonists or to any excipients used in the formulation.
• Omez DSR+ should not be used whenever stimulation of gastrointestinal motility might be dangerous such as in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation.
• Omez DSR +is contraindicated in patients with prolactinoma (a prolactin releasing pituitary tumour).